中国P站

Mucosal vaccines; IgA; pIgR; Nanoparticles; Adjuvants; Gut microbiota; Plant-based vaccines; Immune response; Vaccine delivery; Mucosal immunity

Introduction

Mucosal surfaces represent the body's primary defense against numerous pathogens, relying on innate immune responses like antimicrobial peptides and mucus production [1].

The polymeric Ig Receptor (pIgR) facilitates the transport of IgA, a critical component of adaptive mucosal immunity [1].

Consequently, mucosal vaccine strategies aim to bolster immune responses at these initial entry sites [1].

The pIgR plays an essential role in transporting IgA and IgM across epithelial cells into the mucosal lumen, facilitating antibody-mediated neutralization of pathogens and immune exclusion [2].

Understanding the intricacies of pIgR trafficking and its regulation is paramount for developing effective mucosal vaccines [2].

Targeting vaccines to mucosal surfaces can generate both potent mucosal and systemic immune responses [3].

This can be achieved by using adjuvants that stimulate mucosal immune cells and designing delivery systems to enhance antigen uptake by antigen-presenting cells in the mucosa [3].

Nanoparticles show promise as delivery systems for mucosal vaccines, protecting antigens from degradation, improving uptake by immune cells, and allowing for targeted delivery to specific mucosal sites [4].

Optimization of these nanoparticle-based vaccines is an ongoing area of research [4].

The gut microbiota significantly influences mucosal immunity [5].

Modulating the gut microbiota through prebiotics or probiotics can improve the effectiveness of mucosal vaccines [5].

Elucidating the interaction between the microbiota and mucosal immunity is therefore vital for vaccine development [5].

Plant-based vaccine delivery systems offer a cost-effective and scalable approach to mucosal vaccination [6].

Plants can be engineered to express vaccine antigens for oral delivery, potentially improving vaccine accessibility, particularly in developing countries [6].

Live attenuated vaccines are capable of eliciting strong mucosal and systemic immune responses [7].

However, the risk of reversion to virulence remains a concern [7].

Genetic engineering is being used to create safer and more effective live attenuated mucosal vaccines [7].

Subunit vaccines, while safer than live attenuated vaccines, are often less immunogenic [8].

Adjuvants and delivery systems are needed to enhance the immunogenicity of subunit mucosal vaccines [8].

Novel adjuvants specifically targeting mucosal immune cells are under development [8].

Several mucosal vaccines have been approved for human use, including those against influenza, rotavirus, and polio [9].

These vaccines have demonstrated efficacy in preventing mucosal infections [9].

However, there is a continuing need for improved mucosal vaccines against other important pathogens [9].

Developing effective mucosal vaccines necessitates a multidisciplinary approach, involving immunologists, virologists, microbiologists, and engineers [10].

Collaboration and innovation are essential for overcoming the challenges in mucosal vaccine development and improving global health [10].

Description

Mucosal surfaces are the primary point of entry for many pathogens, making them a critical target for vaccine development [1]. The innate immune system, including antimicrobial peptides and mucus production, provides the first line of defense at these sites [1]. Furthermore, the polymeric Ig Receptor (pIgR) transports IgA, contributing significantly to adaptive mucosal immunity [1]. Mucosal vaccine strategies aim to amplify these immune responses directly at the site of pathogen entry [1].

The pIgR plays a crucial role in transporting IgA and IgM across epithelial cells into the mucosal lumen, a process essential for antibody-mediated neutralization and immune exclusion [2]. Understanding the mechanisms governing pIgR trafficking and regulation is vital for designing effective mucosal vaccines [2]. Current research explores various approaches for subunit vaccine delivery, including the use of plants as a production and delivery platform [2, 6].

Targeting vaccines directly to mucosal surfaces can elicit robust mucosal and systemic immune responses [3]. Effective strategies involve using adjuvants that stimulate mucosal immune cells and employing delivery systems that enhance antigen uptake by antigen-presenting cells in the mucosa [3]. Nanoparticles have emerged as promising delivery systems, offering protection against antigen degradation and improved uptake by immune cells, with the potential for targeted delivery to specific mucosal sites [4]. Optimizing nanoparticle-based mucosal vaccines is an active area of investigation [4].

The gut microbiota significantly influences mucosal immunity [5]. Modulating the gut microbiota through interventions like prebiotics or probiotics can enhance the efficacy of mucosal vaccines [5]. Understanding the complex interplay between the microbiota and mucosal immunity is therefore critical for advancing vaccine development [5]. While live attenuated vaccines can induce strong immune responses, safety concerns related to reversion to virulence persist [7]. Advances in genetic engineering are being applied to develop safer and more effective live attenuated mucosal vaccines [7]. Subunit vaccines, though safer, often require adjuvants and delivery systems to boost their immunogenicity [8]. Novel adjuvants specifically targeting mucosal immune cells are under development to address this challenge [8]. Several mucosal vaccines are already licensed for human use, including those against influenza, rotavirus, and polio, demonstrating the feasibility of this approach [9]. However, there is a continuing need for improved mucosal vaccines to combat other significant pathogens [9].

Successful mucosal vaccine development demands a multidisciplinary effort, bringing together immunologists, virologists, microbiologists, and engineers [10]. Collaboration and innovation are crucial for overcoming the existing challenges and improving global health through effective mucosal vaccination [10]. Plant-based edible vaccines offer a cost-effective approach with challenges and potential [6].

Conclusion

Mucosal surfaces are key entry points for pathogens, defended by innate and adaptive immune responses. The polymeric Ig Receptor (pIgR) transports IgA, crucial for mucosal immunity, making mucosal vaccine targeting essential. Strategies involve adjuvants stimulating mucosal immune cells and delivery systems enhancing antigen uptake. Nanoparticles protect antigens, enhance uptake, and target specific sites, while the gut microbiota significantly shapes mucosal immunity, modulated by prebiotics/probiotics to boost vaccine efficacy. Plant-based systems offer cost-effective vaccine delivery, engineered for oral administration, improving accessibility, particularly in developing countries. Live attenuated vaccines elicit strong responses but risk reversion; genetic engineering aims for safer versions. Subunit vaccines, safer but less immunogenic, need adjuvants targeting mucosal immune cells. Licensed mucosal vaccines exist for influenza, rotavirus, and polio, yet improvements are needed for other pathogens. A multidisciplinary approach, involving immunologists, virologists, microbiologists, and engineers, is essential for overcoming challenges and enhancing global health through improved mucosal vaccines.

References

1. Alessia RM, Alessandro G, Irene C (2023) .Pharmaceutics 15:1813.

   , ,

2. Ana LC, José MM, Gerardo R (2021) .Vaccines 9:1490.

   , ,

3. Edel CL, Elaine AM (2016) .Adv Drug Deliv Rev 114:29-53.

   , ,

4. Ana PB, Fábio AC, Oscar B (2018) .Eur J Pharm Biopharm 133:160-175.

   , ,

5. Faria F, Md SR, Nuzhat JT (2023) .Front Immunol 14:1103585.

   , ,

6. Azam D, Ahmad G (2022) .Front Immunol 13:880910.

   , ,

7. Bali P, Prasad SA (2014) .Cell 157:505-15.

   , ,

8. Rohini R, Junaid B, Madhu P (2024) .Semin Immunol 70:101857.

   , ,

9. Jan H, Kevin MS, Koen M (2020) .J Immunol 204:1767-1782.

   , ,

10. José MRR, María CP, María IR (2020) .Front Bioeng Biotechnol 8:586770.

    , ,